Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • Services & Support
  • Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
      • Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicine
    • Browse Research
    • Education Catalog
      • HLA and Search Strategy Resources
      • GVHD Interactive Provider Network Virtual Learning Series
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program

  • Email
  • Print This Page

Acute Myeloid Leukemia (AML): Treatment Options, including BMT, Care and Support

    Sponsored jointly by the National Marrow Donor Program®/Be The Match® and The Leukemia & Lymphoma Society® (LLS).

    Access on-demand activity >

    Release date: July 14, 2017
    Expiration date: December 14, 2018

      Description

      In the United States, approximately 21,380 people will be diagnosed with acute myeloid leukemia (AML) in 2017.1 Timely access to information on treatment options can empower patients to actively participate in their treatment plan. In this free continuing education webinar, speakers will address how molecular testing at diagnosis can help to inform treatment recommendations; the risks and benefits of treatment options for patients with AML; the impact of timely referral for blood and marrow transplant (BMT) on outcomes for patients with high-risk AML; and unique considerations for older adults.

      The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with AML. Attendees are encouraged to submit questions for a Q&A discussion.

      Target Audience

      Hematology oncology and BMT nurses; hematology oncology and BMT social workers at intermediate to advanced levels of practice, experience and licensure; transplant center coordinators; payer case managers and other allied health professionals.  

      Learning Objectives

      • Identify diagnostic tests included in AML panels, including the role of cytogenetics and molecular analysis.
      • Describe risk stratification for treatment planning.
      • Identify approved and emerging treatment options and the role of clinical trials for the treatment of AML.
      • Explain the impact of timely blood and marrow transplantation (BMT) referral.
      • List programs and resources to support patients with acute myeloid leukemia and their caregivers.

      Speakers

      Daniel A. Pollyea, MD, MS
      Associate Professor, University of Colorado School of Medicine
      Clinical Director of Leukemia Services

      Elaina V. Preston, MPH, MSHS, PA-C
      Physician Assistant, Adult Bone Marrow Transplant Service
      Memorial Sloan Kettering Cancer Center

      Accreditation and certification

      Nurses: The National Marrow Donor Program is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (COA). 

      Up to 1.25 contact hours may be claimed for this educational activity.

      Social workers: The Leukemia & Lymphoma Society (LLS), provider #1105 is approved as a provider for social work continuing education by the Association of Social Work Boards www.aswb.org Approved Continuing Education Program (ACE). Approval Period: 12/2014 - 12/2017. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. 

      LLS is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program.

      Social workers will receive 1.25 clinical continuing education hours for this activity.

      Upon completion of this program and submission of the CE activity evaluation, a certificate of completion will be issued to you via email within 30 days.

      Medical technologists: The NMDP is approved as a provider of continuing education in the clinical laboratory sciences through the ASCLS PACE Program. ASCLS PACE® 1861 International Drive, Suite 200, McLean, VA 22102. 

      Up to 1.00 contact hours may be claimed for program #115-021-17. 

      All other health professionals requesting continuing education credit for this activity will be issued a Certificate of Attendance.  

      Assistance for people with disabilities, grievances, questions or for more information, please call (800) 955-4572. 

      Completion Requirement

      Participants must complete and submit the evaluation for the activity in order to receive a continuing education certificate or a certificate of completion. 

      Certificates will be issued via email with 30 days. 

      Questions?

      If you have any questions regarding this activity, email nmdpeducation@nmdp.org.

      1 SEER Cancer Stat Facts: Acute Myeloid Leukemia. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/amyl.html

      Sponsored jointly by:

      NMDP Be The Match Logo     LLS Logo

       

       

       

       

      • Email
      • Print This Page

      Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

      Keep In Touch

      • Contact Us
      • Transplant Enews

      Our Websites

      • Be The Match
      • Be The Match Mexico
      • Be The Match BioTherapies
      • CIBMTR
      • Jason Carter Clinical Trials Search
      National Marrow Donor Program —
      Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
      Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright